These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26794224)

  • 41. Betahistine dihydrochloride versus flunarizine. A double-blind study on recurrent vertigo with or without cochlear syndrome typical of Menière's disease.
    Fraysse B; Bebear JP; Dubreuil C; Berges C; Dauman R
    Acta Otolaryngol Suppl; 1991; 490():1-10. PubMed ID: 1763646
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Long-term therapy of Ménière's disease. Comparison of the effects of betahistine dihydrochloride and hydrochlorothiazide].
    Petermann W; Mulch G
    Fortschr Med; 1982 Mar; 100(10):431-5. PubMed ID: 7040186
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Controlled clinical trial comparing the effect of betahistine hydrochloride and prochlorperazine maleate on patients with Meniére's disease.
    Aantaa E; Skinhoj A
    Ann Clin Res; 1976 Aug; 8(4):284-7. PubMed ID: 793500
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fixed combination of cinnarizine and dimenhydrinate versus betahistine dimesylate in the treatment of Ménière's disease: a randomized, double-blind, parallel group clinical study.
    Novotný M; Kostrica R
    Int Tinnitus J; 2002; 8(2):115-23. PubMed ID: 14763223
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A study of the efficacy of betahistine in Méniére's syndrome.
    Hommes OR
    Acta Otolaryngol Suppl; 1972; 305():70-9. PubMed ID: 4353751
    [No Abstract]   [Full Text] [Related]  

  • 46. An objective study of the effect of betahistine hydrochloride on hearing and vestibular function tests in patients with Ménière's disease.
    Wilmot TJ
    J Laryngol Otol; 1971 Apr; 85(4):369-73. PubMed ID: 4995451
    [No Abstract]   [Full Text] [Related]  

  • 47. "How should a treatment of Méniére's syndrome be evaluated?" Panel discussion.
    Acta Otolaryngol Suppl; 1972; 305():80-99. PubMed ID: 4146950
    [No Abstract]   [Full Text] [Related]  

  • 48. Histamine in the treatment of vertigo.
    Fischer AJ
    Acta Otolaryngol Suppl; 1991; 479():24-8. PubMed ID: 2068937
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment of Meniere disease with betahistine dimesilate (Aequamen)--double-blind study versus placebo (crossover)].
    Meyer ED
    Laryngol Rhinol Otol (Stuttg); 1985 May; 64(5):269-72. PubMed ID: 3894841
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Treatment of Meniere's disease: conservative or operative].
    Beck C; Arnold W; Lange G; Rudert H; Scherer H
    Laryngol Rhinol Otol (Stuttg); 1985 Dec; 64(12):601-3. PubMed ID: 4087990
    [No Abstract]   [Full Text] [Related]  

  • 51. Vasodilators in menière's syndrome.
    Piercy NM
    Br Med J; 1971 Oct; 4(5782):303. PubMed ID: 5001332
    [No Abstract]   [Full Text] [Related]  

  • 52. [Trimetazidine versus betahistine in vestibular vertigo. A double blind study].
    Kluyskens P; Lambert P; D'Hooge D
    Ann Otolaryngol Chir Cervicofac; 1990; 107 Suppl 1():11-9. PubMed ID: 2240994
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Betahistine: what's new on the agenda?
    Barak N
    Expert Opin Investig Drugs; 2008 May; 17(5):795-804. PubMed ID: 18447604
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Medical treatment in Ménière's disease: avoiding vestibular neurectomy and facilitating postoperative compensation.
    Colletti V
    Acta Otolaryngol Suppl; 2000; 544():27-33. PubMed ID: 10904798
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic strategies in the treatment of Menière's disease: the Italian experience.
    Quaranta N; Picciotti P; Porro G; Sterlicchio B; Danesi G; Petrone P; Asprella Libonati G
    Eur Arch Otorhinolaryngol; 2019 Jul; 276(7):1943-1950. PubMed ID: 30976990
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study.
    Strupp M; Kraus L; Schautzer F; Rujescu D
    J Neurol; 2018 Oct; 265(Suppl 1):80-85. PubMed ID: 29532287
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of long-term betahistine treatment on the clinical outcomes of patients with cochlear Meniere's disease.
    Cheng PC; Wu PH; Chang CM; Lo WC; Liao LJ; Young YH; Cheng PW
    Acta Otolaryngol; 2024 Apr; 144(4):306-312. PubMed ID: 39008429
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The use of betaserk in patients with cochlear-vestibular disorders].
    Kadymov MI; Poliakova TS; Vladimirova TN
    Vestn Otorinolaringol; 1998; (5):49-50. PubMed ID: 9793432
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Méniére's disease: subjective and objective evaluation of medical treatment with betahistine HCl.
    Bertrand RA
    Acta Otolaryngol Suppl; 1972; 305():48-69. PubMed ID: 4353750
    [No Abstract]   [Full Text] [Related]  

  • 60. Comparable efficacy and tolerability between twice daily and three times daily betahistine for Ménière's disease.
    Ganança MM; Caovilla HH; Ganança FF
    Acta Otolaryngol; 2009 May; 129(5):487-92. PubMed ID: 18615332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.